Predicting Response to Perioperative Chemotherapy in Resectable Gastric Cancer: Integrating Clinical, Pathological, Molecular, and Host-Related Biomarkers
Keywords:
gastric cancer, perioperative chemotherapy, FLOT, treatment responseAbstract
Perioperative chemotherapy has transformed the management of locally advanced resectable gastric andgastroesophageal junction adenocarcinoma, with fluorouracil, leucovorin, oxaliplatin, and docetaxel representinga central contemporary regimen. However, therapeutic benefit is heterogeneous. Some patients achieve profound pathological regression and durable survival, whereas others experience minimal tumor response
Downloads
References
Cunningham D, Allum WH, Stenning SP, et al. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N Engl J Med. 2006;355(1):11-20. doi:10.1056/NEJMoa055531.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.


